A preplanned Data Safety Monitoring Board analysis of @ of @ randomized patients who completed the study revealed that the primary endpoint of hyponatremia correction was met by @ of @ patients who received tolvaptan and by @ of @ patients who received placebo ( @ % vs @ % ; P < @ ) , which met the study stopping rule for superiority .